NCT02581527 (RIFASHORT) is a Phase 3 clinical trial of Rifampicin in Pulmonary Tuberculosis, sponsored by St George's, University of London.

Who is sponsoring NCT02581527?

NCT02581527 is sponsored by St George's, University of London.

What drugs are being tested in NCT02581527?

Interventions in NCT02581527: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide.

What condition does NCT02581527 study?

NCT02581527 studies Pulmonary Tuberculosis.

Is NCT02581527 still recruiting?

NCT02581527 is currently completed. Last updated 27 April 2023.

Last reviewed 2023-04-27 · How we verify

NCT02581527: RIFASHORT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

Completed Phase 3 Last updated 27 April 2023

What this trial tests

Phase 3 trial testing Rifampicin in Pulmonary Tuberculosis in 672 participants. Completed in 31 July 2022.

Timeline

1 February 2017

Primary endpoint
1 January 2022

31 July 2022

Quick facts

Lead sponsor	St George's, University of London
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	672
Start date	1 February 2017
Primary completion	1 January 2022
Estimated completion	31 July 2022
Sites	6 locations across Pakistan, Peru, Botswana, Guinea, Uganda, Nepal

Drugs / interventions tested

Rifampicin (Rifampicin) — full drug profile →
Isoniazid (ISONIAZID) — full drug profile →
Ethambutol (ETHAMBUTOL) — full drug profile →
Pyrazinamide (PYRAZINAMIDE) — full drug profile →

Conditions studied

Pulmonary Tuberculosis — all drugs for Pulmonary Tuberculosis →

Sponsor

St George's, University of London

Who can join

Adults 18 to 65, any sex, with Pulmonary Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this trial, the investigators are assessing whether giving an increased dose of rifampicin to patients receiving the standard treatment for tuberculosis is safe and, when given for 4 months only, will also result in greater and faster killing of the tubercle bacillus in the lungs and result in relapse rates similar to those found in the World Health Organisation (WHO) recommended standard 6 month regimen.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

New developments in tuberculosis diagnosis and treatment.
Gill CM, Dolan L, Piggott LM, McLaughlin AM. · · 2022 · cited 84× · PMID 35284018 · DOI 10.1183/20734735.0149-2021
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.
Dartois V, Dick T. · · 2024 · cited 68× · PMID 38418662 · DOI 10.1038/s41573-024-00897-5
High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.
Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, et al · · 2019 · cited 60× · PMID 30870476 · DOI 10.1371/journal.pone.0213718
The present state of the tuberculosis drug development pipeline.
J Libardo MD, Boshoff HI, Barry CE. · · 2018 · cited 58× · PMID 30144650 · DOI 10.1016/j.coph.2018.08.001
Preclinical Efficacy Testing of New Drug Candidates.
Nuermberger EL. · · 2017 · cited 53× · PMID 28643624 · DOI 10.1128/microbiolspec.tbtb2-0034-2017
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg<sup>-1</sup> rifampicin.
Te Brake LHM, de Jager V, Narunsky K, Vanker N, et al · · 2021 · cited 49× · PMID 33542056 · DOI 10.1183/13993003.00955-2020
Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Grace AG, Mittal A, Jain S, Tripathy JP, et al · · 2019 · cited 45× · PMID 31828771 · DOI 10.1002/14651858.cd012918.pub2
Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.
Ernest JP, Strydom N, Wang Q, Zhang N, et al · · 2021 · cited 40× · PMID 32806997 · DOI 10.1146/annurev-pharmtox-030920-011143

Verify or expand the search:

Other trials of Rifampicin

Trials testing the same drug.

NCT06191692 — 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam · Phase 3 · not yet recruiting
NCT07196449 — Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects · Phase 1 · active not recruiting
NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
NCT05994742 — An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM · Phase 3 · active not recruiting
NCT06255951 — Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subje · Phase 1 · completed

Other recruiting trials for Pulmonary Tuberculosis

Currently open trials in the same condition.

NCT07209761 — A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis · Phase 3 · recruiting
NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
NCT07186478 — I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis · NA · active not recruiting
NCT06649721 — Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort · Phase 3 · active not recruiting
NCT06528418 — Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · recruiting

Other St George's, University of London trials

Trials by the same sponsor.

NCT07012421 — Community Antibiotic Use, Susceptibility and ResisTance Among Patients With Urinary Tract Infections (CAST-UTI) · recruiting
NCT06411405 — Using Machine Learning to Model Early-onset Neonatal Sepsis Risk in Uganda and Zimbabwe · unknown
NCT05950984 — Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK) · completed
NCT05855889 — Observational Study of the Management of Infants With Congenital CMV · recruiting
NCT06159218 — Eosinophilic Oesophagitis Assessment With String Testing · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02581527 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St George's, University of London
Last refreshed: 27 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02581527.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing